Sign in
Taking people in United StatesNo phase

Muscle and movement changes with anti-obesity medications and exercise

Studies body composition changes in adults with obesity taking medication, with or without exercise.

Key facts

Who runs it
University of Kansas Medical Center
Where
Kansas City, United StatesSee the site
Trial code
Registry title
Muscle and Movement With Anti-Obesity Medications
Status
Recruiting
People taking part
40 people, planned
Started
1 Dec 2024
Planned end
Sept 2026
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Standard Medical Care (SMC)
  • Monitoring Contacts
  • Aerobic Training
  • Resistance Training
  • Nutrition Education
Record updated
11 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with obesity who are about to start semaglutide or tirzepatide. It studies whether exercise changes muscle, fat and bone changes during treatment.

Age
Randomized study: 18 to under 60 years. Observational study: over 60 years.
Sex
Males and females can join.
Disease stage
BMI over 27.0 kg/m2 with at least one weight-related complication (high blood pressure, abnormal blood fats, sleep apnea or heart and blood vessel disease), or BMI over 30 kg/m2 without complications.
Earlier treatment
Newly prescribed semaglutide or tirzepatide for obesity, approved for treatment, and agreeing to take it for at least 6 months. The person is recruited before starting it.

Main reasons for not taking part

  • Type 2 diabetes
  • Regular exercise: over 60 min/week of moderate-to-vigorous exercise in the past 3 months
  • Weight loss of over 3% in the past 3 months, or past weight-loss surgery
  • Pregnant, pregnant in the past 6 months, or planning pregnancy
  • Serious heart problems, or resting blood pressure over 160/100 mmHg

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Both males and females of all race/ethnic groups are eligible for participation in this study
  • Age: Randomized Study: Adults that are 18 to <60 years of age. Observational Study: Adults that are >60 years of age
  • Newly prescribed AOM (semaglutide, tirzepatide) for the treatment of obesity, approval for treatment (pharmacy, insurance, etc.), and the participant agreeing to start this treatment and continue treatment for at least 6 months (the participant will be recruited prior to this medication being initiated)
  • Body mass index (BMI) of >27.0 kg/m2 with at least one weight-related complication (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease) provided it this does not compromise the ability to safely complete the screening or outcome measures or to engage in the prescribed exercise interventions), or >30 kg/m2 without weight-related complications. Enrollment will not be limited based on an upper BMI level provided that the participant meets the other eligibility requirements. However, weight or size limits of the dual-energy x-ray absorptiometry (DXA) system that is used to assess body composition must not be exceeded
  • Ability to provide informed consent prior to participation in this study
  • Clearance from the study physician for meeting all eligibility criteria for this study

Who cannot take part

  • Current congestive heart failure, angina, uncontrolled arrhythmia, symptoms indicative of an increased acute risk for a cardiovascular event, prior myocardial infarction or history of cardiomyopathy, coronary artery bypass grafting or angioplasty, conditions requiring chronic anticoagulation (i.e., recent or recurrent DVT)
  • Resting systolic blood pressure of >160 mmHg or resting diastolic blood pressure of >100 mmHg. If medicated for blood pressure control, the medication dose needs to be stable for >6 months
  • Type 2 diabetes
  • History of metabolic/bariatric surgery
  • Report a current medical condition or treatment for a medical condition that could affect body weight or contradict engagement in any aspect of the outcome measures or interventions
  • History of muscle conditions that may impact the quality of muscle or response to the study interventions (e.g., myopathy, muscular dystrophy, rhabdomyolysis, etc.)
  • Eating disorders that would contraindicate weight loss or physical activity
  • Current psychological condition that is untreated, hospitalization for a psychological condition within the past 12 months, or not being on a stable dose of treatment for at least 6 months
  • Report moderate-to-vigorous exercise for >60 min/week, and >1 day of structured cardiovascular or resistance exercise over the past 3 months
  • Report sustained weight loss of >3% in the past 3 months
  • Females who are pregnant, pregnant within the past 6 months, or reporting a planned pregnancy during the study period
  • Alcohol or substance abuse
  • Report plans to relocate to a location not accessible to the study site or having employment, personal, or travel commitments that prohibit attendance at scheduled intervention sessions or assessments

Where in United States

  • University of Kansas Medical CenterKansas City, United StatesContact: Renee J. Rogers, Ph.D.Taking people

About the trial

What the trial wants to find out

The goal of this clinical trial is to learn about changes in body composition related to obesity medication use, and whether aerobic or resistance exercise training will impact these body composition changes. It will also provide information about whether aerobic or resistance exercise training has additional benefits on other health and fitness measurements. The main questions it aims to answer are:

Read full original descriptionShow less

* Is there a difference in the change in body composition (fat mass, lean mass, muscle mass, and bone content) between the standard medical care and the exercise conditions (aerobic training and resistance training)? * Is there a difference in the change in body weight and BMI between the standard medical care and the exercise conditions (aerobic training and resistance training)? * Is there a difference in the change in cardiorespiratory fitness between the standard medical care and the exercise conditions (aerobic training and resistance training)? * Is there a difference in how much physical activity is completed between the standard medical care and the exercise conditions (aerobic training and resistance training)? * Is there a difference in the change in physical function between the standard medical care and the exercise conditions (aerobic training and resistance training)? * Is there a difference in the change in muscle strength between the standard medical care and the exercise conditions (aerobic training and resistance training)? * Is there a difference in the change in resting blood pressure between the standard medical care and the exercise conditions (aerobic training and resistance training)? * Is there a difference in the change in food intake between the standard medical care and the exercise conditions (aerobic training and resistance training)? * Is there a difference in the change in health-related quality of life between the standard medical care and the exercise conditions (aerobic training and resistance training)?

Participants will:

* Participate in an intervention for a period of 6 months that involves being assigned to a no exercise/standard medical care condition, or a supervised exercise condition (aerobic training or resistance training). * Visit the clinical before starting the study and at 6 months to complete study measurements of their body composition and other measurements to monitor their progress. * Complete a brief monitoring session at weeks 6, 12, and 18 across the 6 months. * Complete supervised exercise sessions at the research center 3x per week for 6 months (Participants in the exercise groups only: aerobic training or resistance training).

The 3 groups in the trial

  • Standard Medical CareExisting treatment, for comparison

    Standard Medical Care will continue to receive their regular standard clinical care during the 6-month intervention period of this study and will also receive brief contacts from the research staff at weeks 6, 12, and 18.

    Treatment: Standard Medical Care (SMC), Monitoring Contacts, and Nutrition Education

  • Standard Medical Care plus Aerobic TrainingTreatment being tested

    Standard Medical Care plus Aerobic Training will continue to receive their regular standard clinical care during the 6-month intervention period of this study and will also receive supervised aerobic exercise in addition to brief contacts from the research staff at weeks 6, 12, and 18.

    Treatment: Standard Medical Care (SMC), Monitoring Contacts, Aerobic Training, and Nutrition Education

  • Standard Medical Care plus Resistance TrainingTreatment being tested

    Standard Medical Care plus Resistance Training will continue to receive their regular standard clinical care during the 6-month intervention period of this study and will also receive supervised resistance exercise in addition to brief contacts from the research staff at weeks 6, 12, and 18.

    Treatment: Standard Medical Care (SMC), Monitoring Contacts, Resistance Training, and Nutrition Education

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Muscle Quantity and Quality, With and Without Exercise, Combined With Anti-Obesity Medications
Plain-language title
Muscle and movement changes with anti-obesity medications and exerciseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Publications
Record updated
11 May 2026